Science & Technology
An R2 non-neuroinvasive herpes simplex virus type 2 vaccine
Department of Health and Human Services — National Institutes of Health
Opportunity #: 4R42AI177202-02
Award Ceiling
$1.4M
Award Floor
$1.4M
Close Date
May 31, 2026
77 days leftTotal Funding
$1.4M
Expected Awards
1
Posted Date
Jun 1, 2024
Cost Sharing Required
No
Grants.gov ID
sbir-4R42AI177202-02
Description
STTR Phase Phase II award: "An R2 non-neuroinvasive herpes simplex virus type 2 vaccine" awarded to THYREOS INC in OAK PARK, Illinois. Funded by Department of Health and Human Services (National Institutes of Health). Award amount: $1,366,806. The SBIR/STTR programs fund innovative research and development by small businesses, with Phase I for feasibility studies and Phase II for full R&D.
Eligible Applicants
Small businesses
Apply on Grants.gov
Always verify details and apply through the official Grants.gov portal. Information here may not reflect the latest changes.
View on Grants.govDisclaimer: This information is sourced from Grants.gov and may not reflect the most current details. Always verify eligibility requirements, deadlines, and application procedures on the official program website before applying.